• Melanie Hamilton, Wing S Kwok, Arielle Hsu, Stephanie Mathieson, Danijela Gnjidic, Richard Deyo, Jane Ballantyne, Von KorffMichaelMKaiser Permanente Washington Health Research Institute, Seattle, WA, United States., Fiona Blyth, and LinChung-Wei ChristineCCInstitute for Musculoskeletal Health, Sydney, Australia.Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia..
• Institute for Musculoskeletal Health, Sydney, Australia.
• Pain. 2023 Mar 1; 164 (3): 485493485-493.

AbstractIn response to the overuse of prescription opioid analgesics, clinical practice guidelines encourage opioid deprescribing (ie, dose reduction or cessation) in patients with chronic noncancer pain. Therefore, this study evaluated and compared international clinical guideline recommendations on opioid deprescribing in patients with chronic noncancer pain. We searched PubMed, EMBASE, PEDro, National Institute for Health and Care Excellence (United Kingdom), and MAGICapp databases from inception to June 4, 2021, with no language or publication restrictions. In addition, we searched the National Guideline Clearinghouse and International Guideline Network databases from inception to December 2018. Two independent reviewers conducted the initial title and abstract screening. After discrepancies were resolved through discussion, 2 independent reviewers conducted the full-text screening of each potentially eligible reference. Four independent reviewers completed the prepiloted, standardized data extraction forms of each included guideline. Extracted information included bibliographical details; strength of recommendations; and the outcomes, such as when and how to deprescribe, managing withdrawal symptoms, additional support, outcome monitoring, and deprescribing with coprescription of sedatives. A narrative synthesis was used to present the results. This study found that clinical practice guidelines agree on when and how to deprescribe opioid analgesics but lack advice on managing a patient's withdrawal symptoms, outcome monitoring, and deprescribing with coprescription of sedatives. Quality assessment of the guidelines suggests that greater discussion on implementation and dissemination is needed.Copyright © 2022 International Association for the Study of Pain.

34 keywords...

hide…